Further results from the two phase 3 trials of the omega-3 fatty acid product ethyl eicosapentaenoic acid (EPA) (AMR101, Amarin), which showed the agent reduced triglycerides without increasing low-density lipoprotein (LDL) and reduced the number of atherogenic particles, were presented last week at the American Heart Association (AHA) 2011 Scientific Sessions.
The Heart.org - November 24, 2011


.png)







